Covering the Cover Gastroenterology

Slides:



Advertisements
Similar presentations
Covering the Cover Gastroenterology
Advertisements

Covering the Cover Gastroenterology
Volume 145, Issue 4, Pages (October 2013)
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals  Susanna Naggie, Mark S. Sulkowski  Gastroenterology 
Volume 145, Issue 4, Pages e1 (October 2013)
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Volume 135, Issue 4, Pages (October 2008)
Covering the Cover Gastroenterology
Covering the Cover Gastroenterology
Volume 154, Issue 4, Pages (March 2018)
Covering the Cover Gastroenterology
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Covering the Cover Gastroenterology
Covering the Cover Gastroenterology
Is HCV Infection a Neurologic Disorder?
Outcomes Among Living Liver Donors
Covering the Cover Gastroenterology
This Month in Gastroenterology
Ira J. Fox, Stephen C. Strom  Gastroenterology 
Volume 142, Issue 4, Pages (April 2012)
Covering the Cover Gastroenterology
Covering the Cover Gastroenterology
Covering the Cover Gastroenterology
Michael Biermer, Thomas Berg  Gastroenterology 
Volume 155, Issue 4, Pages (October 2018)
Covering the Cover Gastroenterology
Volume 135, Issue 4, Pages (October 2008)
Volume 150, Issue 4, Pages (April 2016)
Jean-Michel Pawlotsky  Gastroenterology 
Volume 143, Issue 5, Pages e6 (November 2012)
A. Sidney Barritt, Michael W. Fried  Gastroenterology 
Update on the Use of Vonoprazan: A Competitive Acid Blocker
Volume 135, Issue 5, Pages (November 2008)
New HCV therapies on the horizon
Covering the Cover Gastroenterology
Covering the Cover Gastroenterology
Covering the Cover Gastroenterology
Christoph Sarrazin, Stefan Zeuzem  Gastroenterology 
Volume 142, Issue 6, Pages (May 2012)
Covering the Cover Gastroenterology
Rafael Esteban, Maria Buti  Gastroenterology 
Reduced Mortality Rates Following Elective Percutaneous Liver Biopsies
Covering the Cover Gastroenterology
Volume 133, Issue 2, Pages (August 2007)
Ashwin N. Ananthakrishnan, David Lieberman  Gastroenterology 
Covering the Cover Gastroenterology
Covering the Cover Gastroenterology
Volume 132, Issue 1, Pages 5-6 (January 2007)
Covering the Cover Gastroenterology
Covering the Cover Gastroenterology
Volume 123, Issue 4, Pages (October 2002)
Covering the Cover Gastroenterology
Volume 150, Issue 7, Pages (June 2016)
Covering the Cover Gastroenterology
The Dawning of a New Editorial Board for Gastroenterology
Covering the Cover Gastroenterology
Covering the Cover Gastroenterology
Volume 156, Issue 6, Pages (May 2019)
Changing of the Guards: 2011–2016 Gastroenterology Team
Volume 139, Issue 6, Pages e1 (December 2010)
Reinvesting in US Biomedical Research—The Time is Now
Covering the Cover Gastroenterology
Covering the Cover Gastroenterology
Covering the Cover Gastroenterology
Electronic Clinical Challenges and Images in GI
Controversies in Liver Transplantation for Hepatitis C
This Month in Gastroenterology
The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.
Covering the Cover Gastroenterology
Presentation transcript:

Covering the Cover Gastroenterology Anson W. Lowe, Richard H. Moseley  Gastroenterology  Volume 145, Issue 4, Pages 699-702 (October 2013) DOI: 10.1053/j.gastro.2013.08.043 Copyright © 2013 AGA Institute Terms and Conditions

Figure 1 Actuarial probability of survival free of relapse defined as a CDAI score >175 in patients treated with azathioprine and placebo. Gastroenterology 2013 145, 699-702DOI: (10.1053/j.gastro.2013.08.043) Copyright © 2013 AGA Institute Terms and Conditions

Figure 2 Electron micrographs (EM) with the presence of microvillous inclusions (arrows) in the CDC42 KO mice (iii) compared with the heterozygote controls (i). (ii, iv) Labeling for the apical protein alkaline phosphatase. Gastroenterology 2013 145, 699-702DOI: (10.1053/j.gastro.2013.08.043) Copyright © 2013 AGA Institute Terms and Conditions

Figure 3 Combination treatment of NA808 with PEG-IFN or direct-acting antiviral agents exhibits robust anti-HCV activity in chimeric mice with humanized liver. (A−D) Median change from baseline of serum HCV-RNA over the 14-day monotherapy or combination therapy of NA808 (5 mg/kg/d, intravenously) with PEG-IFN (A: 30 μg/kg/twice weekly, subcutaneously), RO-9187 (B: 1000 mg/kg/d, orally), HCV-796 (C: 100 mg/kg/d, orally), or telaprevir (400 mg/kg/d, orally) and/or HCV-796 (D). (E) HCV-RNA levels in livers of HCG9-infected chimeric mice at the end of each treatment. Error bars = SD. (∗P < .05). Gastroenterology 2013 145, 699-702DOI: (10.1053/j.gastro.2013.08.043) Copyright © 2013 AGA Institute Terms and Conditions